Semaglutide for Polycystic Ovary Syndrome

This trial aims to explore how semaglutide, a medication, could potentially help women with Polycystic Ovary Syndrome (PCOS). Researchers seek to determine if semaglutide can manage symptoms associated with PCOS. Suitable candidates for this trial have a PCOS diagnosis, a body mass index (BMI) over 30, and are not currently using hormone-based contraceptives. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this potentially beneficial treatment.

You may need to stop taking certain medications, especially if you are using hormone-containing contraceptives, insulin, or specific fertility treatments like letrozole or clomiphene citrate. The trial does not specify a washout period, but these medications are excluded from participation.

Research has shown that semaglutide is a safe treatment for women with Polycystic Ovary Syndrome (PCOS). Commonly used for Type 2 diabetes, this medication can also be safely used by women with PCOS. It belongs to a group of treatments known as GLP-1 receptor agonists, which help with weight loss and are generally well-tolerated.

Semaglutide is unique because it offers a new approach to managing Polycystic Ovary Syndrome (PCOS) by targeting the GLP-1 receptor, which is different from the hormonal or insulin-sensitizing treatments typically used. Most current treatments for PCOS focus on hormonal regulation or improving insulin sensitivity, like birth control pills and metformin. Semaglutide, originally developed for diabetes, has shown promise in regulating appetite and metabolism, which could address weight management issues often associated with PCOS. Researchers are excited because semaglutide could offer a dual benefit of metabolic regulation and weight loss, potentially improving overall health outcomes for women with PCOS.

Research shows that semaglutide, the investigational treatment in this trial, can help women with Polycystic Ovary Syndrome (PCOS). Studies have found that semaglutide aids nearly 80% of women with PCOS who are obese and haven't achieved weight loss through lifestyle changes. It also improves body mass index (BMI) and cholesterol levels, which are crucial for managing PCOS. Additionally, semaglutide reduces waist size, lowers blood fat levels, and decreases testosterone levels, all beneficial for women with PCOS. These findings suggest that semaglutide may help manage PCOS symptoms.³⁴⁵⁶⁷